Citations

Clear

148 citation(s) found for "Ho, Carole".

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11

10.6004/jnccn.2025.0007 | PMID 39938471 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Andrews, Jack R. , Kim, Yohan , Horjeti, Edlira , Arafa, Ali , Bruycker, Aurélie De , Phillips, Ryan , Song, Daniel Y. , Sartor, Oliver , Orme, Jacob J. , Chaudhuri, Aadel A. , Kiess, Ana P. , Sutera, Philip , Mercier, Carole , Arafa, Ali T. , Gunn, Heather , De Bruycker, Aurélie , Phillips, Ryan , Song, Daniel , Childs, Daniel S , Sartor, A Oliver , Orme, Jacob J , Chaudhuri, Aadel A , Tran, Phuoc T , Kiess, Ana , Sutera, Philip , Mercier, Carole , Ost, Piet , Park, Sean S , Lucien, Fabrice , Gunn, Heather , Childs, Daniel S. , Park, Sean S. , Lucien, Fabrice

Mayo Clinic

Clinical Cancer Research | January 16, 2025 | Volume: 31 | Issue: 6 | Pages: 1142-1149

10.1158/1078-0432.ccr-24-3027 | PMID 39820657 Get It

Abstract Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA+) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA+EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA+EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months (P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months (P = 0.003) for PSMA+EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA+EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA+EV was predictive of benefit from SABR (P = 0.012). Conclusions: PSMA+EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA+EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.
An X-linked long non-coding RNA, PTCHD1-AS, regulates autistic behaviors in humans and in mice
Scherer, Stephen W. , Bradley, Clarrisa A. , Ko, Sangyoon Y. , Ralph, Liam T. , D’Abate, Lia , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Tidball, Patrick , Fan, Xiaolian, Howe, Jennifer, Alexandrova, Roumiana, Pellecchia, Giovanna , Casallo, Guillermo, Paton, Tara , Wybenga-Groot, Leanne , Rijke, Jill de , Kadia, Ashish , Salazar, Nelson Bautista , Shum, Carole, Rennie, Olivia , Reuter, Miriam S. , Hoang, Ny , Sarikaya, Ege , Selvanayagam, Thanuja , Rutherford, Annabel, Rivero-Alfaro, Natalia, Marshall, Christian R. , Scala, Marcello , Runke, Cassandra , Kearney, Hutton M. , Francis, David, Plucinicazak, Jill, Iaboni, Alana, Sjaarda, Calvin , Jain, Anjali , Frey, Brendan J., Vorstman, Jacob , Frankland, Paul W. , Scherer, Stephen W , Scala, Marcello , Tian, Meng , Lee, Jinyeol, Liu, Tianyi , Wang, Junhui , Mendes, Marla, Paton, Tara, Engchuan, Worrawat , Thiruvahindrapuram, Bhooma , Trost, Brett , Jin, Fuzi , Díaz-Mejía, J. Javier , MacDonald, Jeffrey R. , Deneault, Éric , Ross, P. Joel, Ellis, James , Georgiou, John , Amini, Aeen Ebrahim, Rivera-Alfaro, Natalia, Marshall, Christian R. , Christodoulou, John , Francis, David I. , Chung, Brian H Y, Pluciniczak, Jill, Wigby, Kristen M. , Nordahl, Christine Wu , Amaral, David Gil , Hudson, Melissa L., Guerin, Andrea, Elsabbagh, Mayada , Landa, Rebecca, Mital, Seema , Lesurf, Robert , Wilson, Michael D. , Ellegood, Jacob , Lerch, Jason P., Lee, Leo J. , Salter, Michael W. , Anagnostou, Evdokia, Collingridge, Graham L.

Mayo Clinic

No container title available | January 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5619348/v1 Get It

Abstract There are ~100 genes or copy number variants (CNVs) used in genetic testing for Autism Spectrum Disorder (ASD, or autism). These genes are protein-coding, and the associated phenotypes often extend beyond socio-behavioral traits seen in autism including cognitive/medical complexities, epilepsy, and ADHD. Here, we characterize 27 males with ASD through whole genome sequencing (WGS), delineating X-chromosome microdeletions that implicate the long non-coding RNA (lncRNA) PTCHD1-AS as an ASD-susceptibility gene (OR=2.56, p=0.01). Two Ptchd1-as knockout (KO) murine models, created by removing the evolutionarily conserved exon-3, show ASD-like features in males, increasing repetitive behaviors and impairing typical social behavior and communication without overt cognitive comorbidities or ADHD-like behaviors. Hippocampus-dependent synaptic function, complex learning, and locomotor activity are unaffected in KO mice. Native nuclear-enriched mouse Ptchd1-as showed sustained expression from post-natal day-7 onward in the dorsal striatum, a predominantly GABAergic brain region implicated in ASD. Multi-omics revealed transcriptomic alterations in striatal oligodendrocyte, astrocyte and neurons impacting myelination and plasticity pathways. Disrupting Ptchd1-as led to reductions in conventional Protein Kinase-C, altered Src and GSK3α/β phosphorylation, and an enhancement of synaptic plasticity (long-term potentiation and long-term depression). Together, these findings implicate striatal molecular and circuit level dysregulation via Ptchd1-as in ASD etiology.
Prevalence, aetiology, and outcomes of native pulmonary regurgitation in the general adult population
Naser, Jwan A. , Ibrahim, Hossam, Andi, Kartik, Scott, Christopher G. , Pellikka, Patricia A. , Kennedy, Austin M , Connolly, Heidi M. , Nkomo, Vuyisile T. , Warnes, Carole A. , Jain, C. Charles , Egbe, Alexander C. , Andi, Kartik , Jain, Charles C, Borlaug, Barry A , Nkomo, Vuyisile T , Scott, Christopher , Pellikka, Patricia A , Enriquez-Sarano, Maurice , Kennedy, Austin M , Naser, Jwan A , Enriquez‐Sarano, Maurice , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 10, 2025 | Volume: 26 | Issue: 4 | Pages: 695-702

10.1093/ehjci/jeaf011 | PMID 39792481 Get It

Abstract Aims Pulmonary regurgitation (PR) after reparative intervention for congenital heart disease has been studied extensively. However, the burden, distribution of causes, and outcome of PR in adults is unknown. The study aimed to evaluate the prevalence, types, and outcomes of moderate/severe PR in adults in the community setting. Methods and results A total of 398 adult residents of Olmsted County who had clinically indicated echocardiography 2004–2023 at Mayo Clinic, Rochester, and had moderate or severe PR were identified retrospectively. The median age was 77 years, 48% were females, and 61 (51%) had severe PR. The age- and sex-adjusted US prevalence was 0.11% (vs. 0.67% for ≥moderate tricuspid regurgitation). Moderate/severe PR was due to pulmonary hypertension in 77%, congenital/iatrogenic in 11%, primary pulmonary valve disease in 2% (88% due to carcinoid), and idiopathic isolated in 10%. In contrast, severe PR was due to congenital/iatrogenic disease in 52%, pulmonary hypertension in 39%, primary PR in 5%, and isolated idiopathic in 3%. The all-cause mortality rate per 100 person-year was 73 in primary (mostly carcinoid) PR, 16 in pulmonary hypertension–related PR (not different vs. propensity-matched patients without PR), and 6 in isolated idiopathic PR (not different vs. matched patients without PR). Conclusion Moderate or severe PR had a lower prevalence vs. TR. The most frequent cause was pulmonary hypertension for ≥moderate PR and congenital/iatrogenic for severe PR. Mortality in patients with acquired ≥moderate PR appeared to be related to the underlying cause, with no excess mortality compared with matched patients without PR. Whether specifically severe PR confers excess mortality requires future investigation.
Estimated aortic pulse wave velocity predicts adverse events in females with thoracic aortic aneurysms
Coutinho, T, Beauchesne, Luc , Chan, K.-L., Dennie, Carole , Wells, George A. , Boodhwani, Munir

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2268 Get It

Abstract Introduction Despite being more common in males, thoracic aortic aneurysms (TAAs) have worse prognosis in females. Females with TAA are 3x more likely to experience acute aortic syndromes, and 40% more likely to die than their male counterparts, but mechanisms underlying this paradox are incompletely understood. The estimated aortic pulse wave velocity (e-PWV) is a marker of aortic stiffness that can be used widely due to its simplicity, as it does not require specialized equipment. We have previously shown that e-PWV was independently associated with faster TAA growth,(1) and that this association was twice as strong in females than males, but the role of e-PWV as a predictor of adverse outcomes in TAA remains unknown. Purpose We sought to evaluate the sex-specific association of e-PWV with adverse outcomes in patients with TAA. Methods We performed a prospective study of 102 males and 48 females with TAA. e-PWV was calculated according to validated equations utilizing age, mean arterial pressure, and presence/absence of cardiovascular risk factors.(2) The primary outcome was a composite of acute aortic syndromes, death, or elective aortic surgery. We used a Cox proportional hazard model to determine the independent association of e-PWV with the primary outcome, adjusted for age, BSA, aneurysm size and location, hypertension, and pulse pressure. Sex-specific models were performed if the interaction of sex*e-PWV was significant (P≤0.05). Univariate logistic regression models were performed to determine the c-statistic for e-PWV in predicting adverse outcomes, and the best e-PWV cutoff for this prediction was established based on sensitivity and specificity. Kaplan-Meier curves were performed using this cut-off. Results A summary of study design and results is presented in Picture 1. Mean age was 62±12 years, 70 (47%) had degenerative etiology, baseline aneurysm size was 46.3±4.3mm, and e-PWV was 9.5±1.9 m/s (not different between sexes, P>0.07 for each). Mean follow-up was 4.6±2.4 years in females and 5.5±2.3 years in males, P=0.031. The primary outcome occurred in 37 (25%) participants (3 dissections, 3 intramural hematomas, 1 aortic rupture, 22 elective surgical repairs and 11 deaths - 3 of which followed surgery). The interaction term sex*e-PWV was significant (P=0.0001), so sex-specific models were performed. e-PWV independently predicted the primary outcome in females (HR for 1m/s increase in e-PWV: 3.4; 95% confidence interval (CI): 1.1-14.7, P=0.033), but not in males (HR: 0.87; 95% CI: 0.50-1.51, P=0.622). In females, e-PWV had a c-statistic of 0.860 for the detection of the primary outcome, with a best e-PWV cutoff of 11.58 m/s (73% sensitivity, 92% specificity). Kaplan-Meier curves for the primary outcome in females using this cutoff are shown in Picture 2. Conclusion e-PWV independently predicts adverse outcomes in females with TAA, highlighting a novel marker for risk stratification and therapeutic targeting.Study summaryKaplan-Meier curves
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, Clifford R. , Andrews, J. Scott , Beach, Thomas G. , Buracchio, Teresa , Dunn, Billy , Graf, Ana, Ho, Carole , Jagust, William J. , Okonkwo, Ozioma C. , Siemers, Eric , Snyder, Heather M. , Carrillo, Marı́a C., Carrillo, María C. , Jack, Clifford R , Hansson, Oskar , McDade, Eric , Molinuevo, José Luís , Pani, Luca , Rafii, Michael S. , Scheltens, Philip , Sperling, Reisa Anne , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 27, 2024 | Volume: 20 | Issue: 8 | Pages: 5143-5169

10.1002/alz.13859 | PMID 38934362 Get It

Abstract The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step‐by‐step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. Highlights We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early‐changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later‐changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
Spirulina (Arthrospira platensis) Improved Nonalcoholic Fatty Liver Disease Characteristics and Microbiota and Did Not Affect Organ Fibrosis Induced by a Fructose-Enriched Diet in Wistar Male Rats
Fakhoury-Sayegh, Nicole , Hamdan, Aya , Lebbos, Sarah, Trak-Smayra, Viviane , Khazzaka, Aline , Dagher‐Hamalian, Carole , Sayegh, Lea N. , Mallah, May , Obeid, Omar , Sayegh, Raymond, Khazzaka, Aline , Sayegh, Lea Nicole , Itani, Tarek M.

Mayo Clinic

Nutrients | May 30, 2024 | Volume: 16 | Issue: 11 | Pages: 1701

10.3390/nu16111701 | PMID 38892633 Get It

Spirulina (Arthrospira platensis) is reported to play a role in improving nonalcoholic fatty liver disease (NAFLD) and intestinal microbiota (IM). To study spirulina’s effects in the improvement of NAFLD characteristics, IM, and pancreatic–renal lesions induced by a fructose-enriched diet, 40 Wistar healthy male rats, weighing 200–250 g, were randomly divided into four groups of 10, and each rat per group was assigned a diet of equal quantities (20 g/day) for 18 weeks. The first control group (CT) was fed a standardized diet, the second group received a 40% fructose-enriched diet (HFr), and the third (HFr-S5) and fourth groups (HFr-S10) were assigned the same diet composition as the second group but enriched with 5% and 10% spirulina, respectively. At week 18, the HFr-S10 group maintained its level of serum triglycerides and had the lowest liver fat between the groups. At the phylae and family level, and for the same period, the HFr-S10 group had the lowest increase in the Firmicutes/Bacteroidetes ratio and the Ruminococcaceae and the highest fecal alpha diversity compared to all other groups (p < 0.05). These findings suggest that at a 10% concentration, spirulina could be used in nutritional intervention to improve IM, fatty liver, metabolic, and inflammatory parameters associated with NAFLD.
Healthcare use and out‐of‐pocket costs for rural family caregivers and care recipients in a randomized controlled trial
Kaufman, Brystana G. , Huang, Ro W. , Holland, Diane E. , Vanderboom, Catherine E., Ingram, Cory , Wild, Ellen, Dose, Ann Marie , Stiles, Carole, Gustavson, Allison M. , Mandrekar, Jay , Houtven, Courtney H. Van , Wild, Ellen M, Griffin, Joan M.

Mayo Clinic

Journal of the American Geriatrics Society | May 3, 2024 | Volume: 72 | Issue: 8 | Pages: 2523-2531

10.1111/jgs.18934 | PMID 38698643 Get It

Abstract Background Rural family caregivers (FCGs) in the United States often experience high economic costs. This randomized controlled trial compared a transitional palliative care intervention (TPC) to support FCGs of seriously ill care recipients (CRs) to an attention control condition. We evaluated the TPC's effect on healthcare use and out‐of‐pocket spending for both FCGs and CRs. Methods TPC FCGs received teaching, guidance, and counseling via video calls for 8 weeks following CR discharge from the hospital. After discharge, a research assistant called all FCGs once a month for up to 6 months or CR death to collect self‐reported healthcare utilization (e.g., outpatient, emergency department, and hospital), out‐of‐pocket healthcare spending (e.g., deductibles and coinsurance), and health‐related travel costs (e.g., transportation, lodging, food) for FCGs and CRs. Incidence rate ratios (IRRs) were estimated using negative binomial regressions. Results The study included 282 FCG–CR dyads across three U.S. states. Follow‐up over the 6‐month period was shortened by high CR mortality rates across both arms (29%), but was similar across arms. TPC reduced nights in the hospital for CR (IRR = 0.75; 95% confidence interval [CI] = 0.56–0. 99). Total out‐of‐pocket spending was not significantly different for TPC versus control. Across both groups, mean out‐of‐pocket spending for dyads was $1401.85, with healthcare payments contributing $1048.58 and transportation expenses contributing $136.79. TPC dyads reported lower lodging costs (IRR = 0.71; 95% CI = 0.56–0.89). Conclusions This study contributes to evidence that palliative care interventions reduce the number of nights in the hospital for seriously ill patients. Yet, overall rural FCGs and seriously ill CRs experience substantial out‐of‐pocket economic costs in the 6 months following hospitalization. Transitional care intervention design should consider impacts on patient and caregiver spending. Clinicaltrials.gov # is NCT03339271.
Targets and treatments in primary CNS lymphoma
Ferreri, Andrés J.M. , Soussain, Carole , Roemeling, Christina A. Von , Tun, Han W. , Grommes, Christian

Mayo Clinic

Leukemia & Lymphoma | April 25, 2024 | Volume: 65 | Issue: 8 | Pages: 1055-1067

10.1080/10428194.2024.2342560 | PMID 38659230 Get It

Abstract 14709: Right Sternal Lead Placement Increases Eligibility for Subcutaneous Defibrillator Implantation in Adults With Congenital Heart Disease
Okamura, Hideo , Bashir, Mohammad U, Webster, Tracy L., Bonnichsen, Crystal R. , Grogan, Martha , Phillips, Sabrina D. , Warnes, Carole A. , Ammash, Naser M., Connolly, Heidi M. , Friedman, Paul A. , McLeod, Christopher J.

Mayo Clinic

Circulation | April 23, 2024 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.14709 Get It

Introduction: The subcutaneous implantable cardioverter defibrillator (S-ICD) is an attractive option for patients with congenital heart disease (CHD) in whom a transvenous system is contraindicated. However, more than 10% of adult patients with CHD fail S-ICD screening due to a large T- to R-wave ratio. We hypothesized right-sternal electrodes may permit S-ICD placement in patients who fail left-sternal screen. Methods: We prospectively screened 40 patients with CHD for S-ICD using the standard proprietary approach. We also screened with right sternal electrodes (with left can electrode position). Results: The mean age of the cohort was 46+/-15 years; 24 males were enrolled. CHD anomalies consisted of tetralogy of Fallot (n=11), Ebstein’s anomaly (n=7), atrial septal defect (n=6), dextro-looped transposition of the great artery (n=5) and other (n=11). Left side screening ECG failed in 9 patients (23%), five of whom passed with right sternal electrodes, increasing the pass rate from 77% to 90%. Figure shows the screening ECG and chest x-ray of a patient who failed in all three vectors on the left side but passed in the alternative vector on the right side and underwent right sided implantation. Conclusions: The addition of right sternal electrodes during screening increases S-ICD eligibility and may avoid thoracotomy for high risk patients with CHD.